Gilead Sciences (GILD) Says UK Court Invalidated Idenix (MRK) 489 Patent
- Wall St falls after recent strong gains, Alphabet shares sink
- Disney Q1 results beat estimates as theme parks business shines
- Affirm Holdings shares sink after earnings miss; cutting 19% of jobs
- CVS Health (CVS) confirms deal to buy Oak Street Health (OSH) for $10.6 billion
- Mattel Q4 results fall short of estimates as challenging macroenvironment weighs
On March 12, 2014, the European Patent Office (EPO) granted Idenix Pharmaceuticals' (NYSE: MRK) European Patent No. 1 523 489 (the ‘489 patent), which corresponds to the Idenix’s U.S. Patent No. 7608600 (‘600 patent) claiming compounds allegedly related to sofosbuvir and their use for treating hepatitis C virus. The same day that the ‘489 patent granted, Gilead Sciences, Inc. (Nasdaq: GILD) filed an opposition with the EPO seeking to revoke the ‘489 patent. Also on that day, Idenix initiated infringement proceedings against Gilead in the United Kingdom (UK), Germany and France alleging that the commercialization of Sovaldi® (sofosbuvir) in those countries would infringe the respective national counterparts of the ‘489 patent. In the UK, a trial was held in October 2014 to determine the issues of infringement and validity of ’489 patent.
On December 1, 2014, the UK court invalidated all claims of the ‘489 patent on multiple grounds. Specifically, the UK court held that the ‘489 patent lacked novelty over Gilead’s prior published patent application claiming the same compounds, the ’489 patent lacked an inventive step because it did not add anything to the knowledge existing at the time and the disclosure in the Idenix’s patent application was insufficient because it did not teach how to make the compounds or show which of the hundreds of billions of compounds claimed would have activity against viruses like the hepatitis C virus. The court also determined that if the ‘489 patent was valid, Gilead’s sale of sofosbuvir would infringe the patent. A corresponding Idenix patent was invalidated in Norway, and Gilead previously prevailed in an interference against Idenix in the U.S. Patent and Trademark Office. In Germany, the court in Düsseldorf has ordered a hearing date of February 3, 2015 to determine the issue of infringement of the Idenix’s German patent. Gilead believes that Idenix’s German patent is invalid for the same reasons as Idenix’s UK and Norwegian patents and for this reason the German court should stay the decision of infringement until the opposition Gilead filed in the EPO has been resolved.
Trials will be held on the corresponding Idenix patents in Canada in January 2015 and Australia in September 2015. A trial date has not been set for the French lawsuit.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biorestorative Therapies (BRTX) Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
- loanDepot (LDI) announces Anthony Hsieh has stepped down as Executive Chairman
- Intel (INTC) Announces 'Editorial: Unlocking the Potential of Generative AI'
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!